A model for harmonizing flow cytometry in clinical trials.
Repository Usage Stats
Complexities in sample handling, instrument setup and data analysis are barriers to the effective use of flow cytometry to monitor immunological parameters in clinical trials. The novel use of a central laboratory may help mitigate these issues.
Published Version (Please cite this version)10.1038/ni1110-975
Publication InfoAmos, M; Aranda, R; Banchereau, J; Boshoff, C; Braun, J; Cho, J; ... Yeh, J-H (2010). A model for harmonizing flow cytometry in clinical trials. Nat Immunol, 11(11). pp. 975-978. 10.1038/ni1110-975. Retrieved from http://hdl.handle.net/10161/14743.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor in Medicine
Thomas N. Denny, MSc, M.Phil, is the Chief Operating Officer of the Duke Human Vaccine Institute (DHVI) and the Center for HIV/AIDS Vaccine Immunology (CHAVI), and a Professor of Medicine in the Department of Medicine at Duke University Medical Center. He is also an Affiliate Member of the Duke Global Health Institute. He has recently been appointed to the Duke University Fuqua School of Business Health Sector Advisory Council. Previously, he was an Associate Professor of Pathology, Laboratory M
Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine
In addition to their ongoing HIV/AIDS-related research activities, the Weinhold Laboratory is focused on utilizing a comprehensive repertoire of highly standardized and formerly validated assay platforms to profile the human immune system in order to identify immunologic signatures that predict disease outcomes. These ongoing studies span a broad range of highly relevant clinical arenas, including: 1) cancer (non-small cell lung cancer, head and neck cancer, glioblastoma neof
Alphabetical list of authors with Scholars@Duke profiles.